4D Molecular Therapeutics Inc’s recently made public that its Chief Legal Officer Bizily Scott unloaded Company’s shares for reported $8165.0 on Sep 16 ’24. In the deal valued at $16.33 per share,500 shares were sold. As a result of this transaction, Bizily Scott now holds 6,781 shares worth roughly $33091.28.
Then, Bizily Scott sold 500 shares, generating $7,500 in total proceeds. Upon selling the shares at $15.00, the Chief Legal Officer now owns 6,781 shares.
Before that, Bizily Scott sold 1,750 shares. 4D Molecular Therapeutics Inc shares valued at $47,442 were divested by the Chief Legal Officer at a price of $27.11 per share. As a result of the transaction, Bizily Scott now holds 6,781 shares, worth roughly $33091.28.
BMO Capital Markets downgraded its 4D Molecular Therapeutics Inc [FDMT] rating to a Market perform from a an Outperform in a research note published on January 13, 2025; the price target was decreased to $15 from $40. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in late November with a ‘”an Underweight”‘ rating. Cantor Fitzgerald also remained covering FDMT and has decreased its forecast on September 23, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Barclays started covering the stock on April 15, 2024. It rated FDMT as “an Overweight”.
Price Performance Review of FDMT
On Tuesday, 4D Molecular Therapeutics Inc [NASDAQ:FDMT] saw its stock jump 2.52% to $4.88. Over the last five days, the stock has lost -23.15%. 4D Molecular Therapeutics Inc shares have fallen nearly -12.39% since the year began. Nevertheless, the stocks have fallen -74.04% over the past one year. While a 52-week high of $36.25 was reached on 01/07/25, a 52-week low of $4.68 was recorded on 01/13/25. SMA at 50 days reached $7.02, while 200 days put it at $16.11.
Levels Of Support And Resistance For FDMT Stock
The 24-hour chart illustrates a support level at 4.76, which if violated will result in even more drops to 4.63. On the upside, there is a resistance level at 5.05. A further resistance level may holdings at 5.21. The Relative Strength Index (RSI) on the 14-day chart is 32.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.70%. Stochastics %K at 11.77% indicates the stock is a buying.
How much short interest is there in 4D Molecular Therapeutics Inc?
A steep rise in short interest was recorded in 4D Molecular Therapeutics Inc stocks on 2024-12-31, dropping by -0.54 million shares to a total of 7.99 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 8.52 million shares. There was a decline of -6.71%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 15, 2024 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $45 price target.
